IVX-411

IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia. It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.